Journal Article

DKFZ-2026-01874

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Secondary autoimmune and inflammatory diseases after allogeneic hematopoietic stem cell transplantation: a retrospective study from the EBMT transplant complications and autoimmune diseases working parties.

Mekinian, A. ; Oganesyan, A. ; Perić, Z. ; Labopin, M. ; Salmenniemi, U. ; Pérez Simón, J. A. ; Verlinden, A. ; Sakellari, I. ; Alzahrani, M. ; Martino, M. ; Baron, F. ; Snowden, J. A. ; Ozdogu, H. ; Kulagin, A. ; Jost, E. ; Torrent, A. ; Benedetti, F. ; De Becker, A. ; François, S. ; Rovira, M. ; Reinhardt, H. C.DKFZ* ; Biffi, A. ; Ringhoffer, M. ; Ambron, P. ; López Lorenzo, J. L. ; Yafour, N. ; Galvagni, A. ; Badoglio, M. ; Moiseev, I. ; Alexander, T. ; Mohty, M. ; Fain, O. ; Greco, R. ; Penack, O.DKFZ*

2026
Springer Nature London

Abstract: Secondary autoimmune and inflammatory diseases (SAIDs) are underrecognized and poorly described after allogeneic hematopoietic stem cell transplantation (allo-HSCT). The standardization of management is hindered by the scarcity of data on epidemiology, pathogenesis, and clinical outcomes. To improve the evidence base, we performed a retrospective multicenter EBMT database study of patients who underwent allo-HSCT between 2005 and 2019 for either hematological malignancy or severe aplastic anemia with available information on SAIDs. We included 129 cases of SAIDs and 14,617 controls. The 5-year incidence of SAIDs was 0.9% (95% confidence interval (CI): 0.7-1.1), and the 10-year incidence was 1.1% (95% CI: 0.9-1.3). The median time from allo-HSCT to the diagnosis of SAIDs was 442 days [interquartile range (IQR): 242-1082]. Overall survival after the onset of SAIDs was 83.4% (95% CI 74.6-89.3) at 2 years and 73.4% (95% CI: 62-82) at 5 years. In multivariate analysis, risk factors significantly associated with SAIDs were bone marrow failure (Hazard Ratio (HR): 3.41 [95% CI, 1.55-7.52], p = 0.002), female donor to male patient (HR 1.77 [95% CI, 1.15-2.73], p = 0.009), and the presence of chronic GvHD (HR 1.61 [95% CI, 1.04-2.51], p = 0.034). SAIDs after allo-HSCT are rare but clinically significant entities requiring further investigations, exploring treatment and prevention strategies, as well as improving diagnostic approaches.

Note: #DKTKZFB9# / #NCTZFB9# / epub

---

Contributing Institute(s):

1. DKTK Koordinierungsstelle Essen/Düsseldorf (ED01)
2. Koordinierungsstelle NCT Berlin (BR01)

Research Program(s):

1. 899 - ohne Topic (POF4-899) (POF4-899)

Appears in the scientific report 2026

---

Database coverage:
; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Current Contents - Life Sciences ; DEAL Springer ; Ebsco Academic Search ; Essential Science Indicators ; IF < 5 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---